Immune-based therapeutic interventions recognizing proteins localized on the cell surface of
cancer cells are emerging as a promising cancer treatment. Antibody-based therapies and …

T-cell redirecting therapies (TCRTs), such as CAR-or TCR T-cells and T-cell engagers, have
emerged as a highly effective treatment modality, particularly in the B-and plasma cell …

Cancer exploits different mechanisms to escape T-cell immunosurveillance, including
overexpression of checkpoint ligands, secretion of immunosuppressive molecules, and …

CAR T-cell products targeting lineage-specific cell-of-origin antigens, thereby eliminating
both tumor and healthy counterpart cells, are currently clinically approved therapeutics in B …

We report a first-in-human clinical trial using chimeric antigen receptor (CAR) T cells
targeting CD37, an antigen highly expressed in B-and T-cell malignancies. Five patients …

While cancer research and care have benefited from revolutionary advances in the ability to
manipulate and study living systems, the field is limited by a lack of synergy to leverage the …

Recurrent and/or refractory (R/R) pediatric acute myeloid leukemia (AML) remains a
recalcitrant disease with poor outcomes. Cell therapy with genetically modified immune …

Chimeric antigen receptor (CAR) T cells are “living drugs” that specifically recognize their
target antigen through an antibody-derived binding domain resulting in T cell activation …

The emergence of immune escape is a significant roadblock to developing effective chimeric
antigen receptor (CAR) T cell therapies against hematological malignancies, including acute …

Despite several small-molecule drugs that have revolutionized the current treatment strategy
for acute myeloid leukemia (AML), hematopoietic stem cell transplantation remains the only …